{"gene":"CCL8","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1992,"finding":"CCL8 (MCP-2) was isolated and characterized as a novel CC chemokine that specifically attracts monocytes but not neutrophils in vitro and in vivo, with a primary structure closely related to MCP-1, establishing it as a monocyte chemoattractant.","method":"Protein purification, peptide sequencing, Boyden chamber chemotaxis assay, intradermal injection in rabbits","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — original isolation with sequencing and functional chemotaxis assay, foundational paper with 358 citations","pmids":["1613466"],"is_preprint":false},{"year":1997,"finding":"CCL8 (MCP-2) uses CCR1 and CCR2B as its functional receptors, as demonstrated by radioiodinated MCP-2 binding to CCR1- and CCR2B-transfected HEK293 cells, competitive displacement, and chemotaxis of transfected cells.","method":"Radioligand binding assay, receptor-transfected cell chemotaxis, competitive displacement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding assay with receptor-transfected cells plus functional chemotaxis, replicated by multiple labs","pmids":["9115216"],"is_preprint":false},{"year":1994,"finding":"CCL8 (MCP-2) attracts human CD4+ and CD8+ T lymphocytes, induces Ca2+ flux via pertussis toxin-sensitive G-protein-coupled receptors, and shares receptors with MCP-1 and MCP-3 as shown by cross-desensitization experiments.","method":"Boyden chamber chemotaxis, cytosolic Ca2+ measurement, pertussis toxin treatment, receptor desensitization assay","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (chemotaxis, Ca2+ flux, desensitization), 309 citations","pmids":["7926371"],"is_preprint":false},{"year":1995,"finding":"CCL8 (MCP-2) activates human basophils and eosinophils, inducing Ca2+ transients, chemotaxis, and mediator release. Cross-desensitization showed CCL8 interacts with receptors for both MCP-1 and RANTES. In IL-3-untreated basophils, MCP-2 acts as a functional inhibitor of CC chemokine actions.","method":"Basophil/eosinophil activation assay, Ca2+ measurement, chemotaxis, receptor desensitization","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with desensitization controls, 86 citations","pmids":["7535823"],"is_preprint":false},{"year":1995,"finding":"CCL8 (MCP-2) acts on human monocytes to induce migration and N-acetyl-beta-D-glucosaminidase release. Cross-desensitization and competitive binding studies showed MCP-2 shares receptors with MCP-1, MCP-3 and also interacts with RANTES/MIP-1 receptors, but not vice versa.","method":"Monocyte migration assay, enzyme release assay, Ca2+ measurement, radiolabeled MCP-1 and MIP-1alpha binding competition","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple functional assays with receptor binding competition, 308 citations","pmids":["7531149"],"is_preprint":false},{"year":1994,"finding":"CCL8 (MCP-2) attracts human eosinophils and cross-desensitizes eosinophil chemotaxis towards RANTES, suggesting CCL8 signals through the RANTES receptor on eosinophils.","method":"Boyden chamber eosinophil chemotaxis, cross-desensitization experiments","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay with cross-desensitization, single study","pmids":["7514401"],"is_preprint":false},{"year":1998,"finding":"CCL8 (MCP-2) binds CCR5 with high affinity, acts as a true CCR5 agonist eliciting chemotaxis and Ca2+ flux in CCR5 transfectants, blocks HIV-1 gp120 binding to CCR5, and preferentially uses CCR5 (over CCR1 or CCR2) on activated T cells.","method":"Radioligand binding to CCR5 transfectants, chemotaxis assay, Ca2+ flux, gp120 competition assay, anti-CCR5 mAb blocking","journal":"Cellular immunology","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution with transfected receptors, multiple orthogonal assays, functional validation","pmids":["9790730"],"is_preprint":false},{"year":1994,"finding":"CCL8 (MCP-2) is chemically synthesized into a biologically active 76-residue chemokine with correct disulfide bridges, is chemotactic for monocytes at ~7.5 ng/ml (comparable to natural MCP-2), and does not induce neutrophil chemotaxis.","method":"Chemical synthesis (Fmoc chemistry), RP-HPLC purification, SDS-PAGE, disulfide bridge formation, monocyte chemotaxis assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with functional validation; confirmed that monocyte selectivity is intrinsic to the chemokine structure","pmids":["8189067"],"is_preprint":false},{"year":1995,"finding":"Synthetic CCL8 (MCP-2) co-elutes and co-migrates with natural MCP-2, has monocyte chemotactic activity at 7.5 ng/ml, and does not attract neutrophils, confirming that the 76-residue folded structure is sufficient for biological activity.","method":"Chemical synthesis, RP-HPLC, SDS-PAGE, monocyte and neutrophil chemotaxis","journal":"Cytokine","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of chemokine from synthetic peptide with functional assay","pmids":["7780043"],"is_preprint":false},{"year":1997,"finding":"The CCL8 gene (SCYA8) was cloned from chromosome 17q11.2, has a conserved three-exon/two-intron structure shared with MCP-1 and MCP-3, and produces a 1.0-kb mRNA predominantly in small intestine, peripheral blood, heart, placenta, lung, skeletal muscle, ovary, colon, and spinal cord.","method":"YAC contig PCR cloning, gene sequencing, Northern blot analysis","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing and Northern blot confirming gene structure and expression pattern","pmids":["9119400"],"is_preprint":false},{"year":1999,"finding":"IFN-gamma induces CCL8 (MCP-2) transcription in fibroblasts through a promoter region between -340 and -301 (relative to transcription start), containing elements recognized by transcription factors identified by EMSA; IL-1beta alone was insufficient but synergized with IFN-gamma for additional induction.","method":"Promoter deletion/luciferase reporter assay, electrophoretic mobility shift assay (EMSA), transfection into diploid fibroblasts and osteosarcoma cells","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 1-2 — promoter deletion mapping with luciferase and EMSA in two cell types","pmids":["10496322"],"is_preprint":false},{"year":2000,"finding":"MMP-9 (gelatinase B) does not cleave CCL8 (RANTES and MCP-2 are left intact by gelatinase B), in contrast to its processing of IL-8 and degradation of CTAP-III, PF-4, and GRO-alpha.","method":"In vitro protease cleavage assay with purified MMP-9 and chemokines, functional neutrophil activation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical assay with purified proteins; 546 citations","pmids":["11023497"],"is_preprint":false},{"year":2009,"finding":"CCL8 (MCP-2) is synergistically induced by combined IFN-gamma + IL-1beta (or IFN-gamma + TLR ligands) in fibroblasts and endothelial cells. The intact CCL8(1-76) is processed into CCL8(6-75) by an extracellular protease, losing chemotactic activity but retaining receptor occupancy and acting as a CCR2 antagonist that inhibits MCP-1/CCL2 and MCP-2 ERK signaling and induces CCR2 internalization.","method":"Cytokine induction assay, N-terminal sequencing of truncated forms, Ca2+ signaling via CCR1/2/3/5-transfected cells, ERK signaling, chemotaxis assay, receptor internalization","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical characterization of natural truncation, functional receptor assays with multiple orthogonal endpoints","pmids":["19224633"],"is_preprint":false},{"year":2011,"finding":"Mouse CCL8 is an agonist for CCR8 (but not CCR2), recruiting IL-5-enriched CCR8+ Th2 cells to allergen-inflamed skin. Ccr8- and Ccl8-deficient mice had markedly reduced eosinophilic inflammation in an atopic dermatitis model, and adoptive transfer confirmed CCR8 as key for Th2 cell skin recruitment.","method":"CCR8/CCR2 signaling assay, Ccl8-/- and Ccr8-/- mouse models, adoptive transfer, chronic atopic dermatitis model, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple knockout models plus receptor specificity assays and adoptive transfer; 257 citations","pmids":["21217759"],"is_preprint":false},{"year":2010,"finding":"CCL8/MCP-2 is a direct target of miR-146a in HIV-1-infected human microglial cells; overexpression of miR-146a prevented HIV-induced CCL8 secretion, consistent with miR-146a binding the CCL8 3' UTR.","method":"miRNA overexpression in primary microglial cells, ELISA for CCL8, HIV-1 infection model, analysis of HIVE brain samples","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 3 — overexpression/knockdown with functional readout but lacks explicit luciferase reporter for miR-146a targeting CCL8 3' UTR in this paper","pmids":["20181935"],"is_preprint":false},{"year":2014,"finding":"The viral HCMV protein LAcmvIL-10 suppresses cellular miRNA hsa-miR-92a, which directly targets the CCL8 3' UTR; loss of hsa-miR-92a de-represses CCL8, increasing its secretion during HCMV latent infection of myeloid progenitor cells.","method":"Primary myeloid progenitor cell latency model, miRNA analysis, secretome proteomics, functional linkage of LAcmvIL-10 to miR-92a to CCL8","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic chain from viral protein to miRNA to CCL8 in primary cells, single study","pmids":["25253336"],"is_preprint":false},{"year":2013,"finding":"Mycobacterium infection induces CCL8/MCP-2 production in macrophages through TLR2/PI3K/Akt and p38 signaling pathways; CCL8 accumulates in TB pleural effusions and its primary receptor CCR5 is expressed on pleural CD4+ T cells.","method":"BCG and M. tuberculosis infection of macrophage cell lines and primary MDMs, signaling inhibitor studies, protein array, qPCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — pathway identified by pharmacological inhibitors with multiple cell types, single study","pmids":["23418602"],"is_preprint":false},{"year":2014,"finding":"BLIMP1 directly represses CCL8 transcription in macrophages. BLIMP1-deficient macrophages express elevated CCL8; CCL8 is chemotactic for γ/δ T cells enriched for IL-17F, and CCL8-mediated Listeria clearance is dependent on γ/δ T cells.","method":"Conditional Blimp1 KO macrophages, transcriptome analysis, Ccl8-/- mice, Listeria monocytogenes infection model, γ/δ T cell depletion","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with transcriptome analysis plus Ccl8 KO and T cell depletion establishing pathway position","pmids":["24477914"],"is_preprint":false},{"year":2008,"finding":"Oncostatin M stimulates CCL8 expression in primary human dermal fibroblasts via ERK1/2 and p38 MAPK pathways (through c-Jun and c-Fos as ERK targets); p38 prolongs CCL8 mRNA half-life by inhibiting tristetraprolin. CCL8 is not regulated by STAT1, STAT3, or STAT5, but STAT5/CIS axis selectively represses CCL1 (not CCL8).","method":"Cytokine stimulation, MAPK inhibitors, siRNA knockdown of c-Jun/c-Fos/STATs, mRNA stability assays, migration assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibitors and siRNA knockdowns defining signaling pathway, multiple orthogonal endpoints","pmids":["18981157"],"is_preprint":false},{"year":2017,"finding":"CCL8 interacts with CCR3 with a dissociation constant of ~1.2 × 10^-7 M measured by quartz crystal microbalance; CCL8 induces CCR3 internalization in vivo within 1 hour and elicits weaker chemotaxis of CCR3-expressing cells compared to CCL11 and CCL24.","method":"Quartz crystal microbalance (QCM) binding assay, CCR3 internalization assay, transwell chemotaxis assay","journal":"BMC immunology","confidence":"Medium","confidence_rationale":"Tier 1-2 — direct in vitro binding measurement plus cellular functional assays, single study","pmids":["29281969"],"is_preprint":false},{"year":2005,"finding":"TRAIL pretreatment abrogates TNF-alpha-induced CCL8 and CXCL10 upregulation in endothelial cells via TRAIL-R1 and TRAIL-R2, and exogenous CCL8 plus CXCL10 restores the proadhesive activity of TNF-alpha, establishing that CCL8 is a key mediator of TNF-alpha-induced leukocyte adhesion to endothelium.","method":"cDNA microarray, neutralizing antibody rescue experiments, agonistic anti-TRAIL receptor antibodies, HL-60 adhesion assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — microarray plus gain-of-function rescue identifies CCL8 as effector; single study","pmids":["15644410"],"is_preprint":false},{"year":2016,"finding":"CCL8 drives Treg recruitment to metastatic lungs via CCR5 signaling; F4/80+ macrophages in metastatic lungs produce CCL8, Tregs in metastatic lungs are enriched for CCR5, and Maraviroc (CCR5 inhibitor) reduces CCL8-driven Treg migration ex vivo and reduces metastatic tumor burden in vivo.","method":"Flow cytometry, ex vivo Treg migration toward CCL8, CCR5 inhibitor treatment, metastatic mouse tumor model","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional migration assay with pharmacological inhibition and in vivo model; single study","pmids":["27471618"],"is_preprint":false},{"year":2019,"finding":"Hypoxia-induced ZEB1 in cervical cancer cells activates CCL8 transcription, which then attracts macrophages via the CCR2-NF-κB pathway, promoting tumor-associated macrophage accumulation and cancer progression.","method":"In vitro macrophage migration assay, chemokine expression array, mechanistic follow-up of ZEB1-CCL8-CCR2 axis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — pathway mechanistically defined in vitro with migration assay and NF-κB pathway; single study","pmids":["31263103"],"is_preprint":false},{"year":2019,"finding":"miR-345-5p directly targets the CCL8 3' UTR (confirmed by luciferase assay), suppressing CCL8 expression; CCL8 activates NF-κB signaling to promote pancreatic cancer cell proliferation and invasion.","method":"Luciferase reporter assay, Western blot, Transwell invasion, NF-κB pathway analysis","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 — direct luciferase confirmation of miRNA targeting plus pathway analysis; single study","pmids":["30841468"],"is_preprint":false},{"year":2018,"finding":"miR-146a-5p directly targets the 3' UTR of CCL8 (confirmed by dual-luciferase reporter assay) in spinal neurons; CCL8 upregulation in the spinal cord mediates visceral pain via CCR5/ERK activation, and intrathecal CCL8 siRNA or miR-146a-5p agomir reduces colitis-induced visceral hyperalgesia.","method":"Dual-luciferase reporter assay, intrathecal injection, siRNA knockdown, neutralizing antibody, colorectal distension pain threshold measurement","journal":"Brain research bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — validated 3' UTR target with in vivo loss-of-function rescue; single study","pmids":["29550454"],"is_preprint":false},{"year":2017,"finding":"CCL8 and its receptor CCR5 are upregulated in the spinal cord following colitis (TNBS model); intrathecal CCL8 neutralizing antibody or CCR5 antagonist reduces visceral hyperalgesia and spinal ERK activation, placing CCL8/CCR5/ERK in a visceral pain signaling pathway.","method":"TNBS colitis mouse model, intrathecal antibody/antagonist injection, ERK phosphorylation assay, MEK inhibitor treatment, pain behavioral testing","journal":"Brain research bulletin","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo loss-of-function with defined signaling endpoint; single study","pmids":["29037608"],"is_preprint":false},{"year":2022,"finding":"In a murine kidney transplant model, donor kidney resident macrophages upregulate CCL8 post-transplant, which promotes recipient monocyte graft infiltration, monocyte differentiation to resident macrophages (further expressing CCL8), and subsequent CCR8+ T cell infiltration; blocking CCL8-CCR8 or depleting donor macrophages reduces early allograft inflammation and improves graft function.","method":"Allogeneic murine kidney transplant model, CCL8-CCR8 blocking antibody, macrophage depletion, flow cytometry","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection with blocking experiments in a defined in vivo transplant model; single study","pmids":["35973731"],"is_preprint":false},{"year":2023,"finding":"Lactate induces CCL8 production in M2 tumor-associated macrophages via AKT/ERK signaling; secreted CCL8 then activates CCR5 on colorectal cancer cells, triggering mTORC1 signaling to promote proliferation and metastasis; CCR5 antagonism or knockdown blocks these effects.","method":"qRT-PCR, Western blot, RNA-seq, wound healing assay, colony formation, CCR5 knockdown/antagonist, allograft mouse model","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods defining CCL8/CCR5/mTORC1 pathway in vitro and in vivo; single study","pmids":["38136340"],"is_preprint":false},{"year":2021,"finding":"CCL8 stimulates collagen production in fibroblasts via ERK1/2 phosphorylation; anti-CCL8 neutralizing antibody treatment in an IgG4-RD mouse model reduces salivary gland inflammation and fibrosis scores.","method":"Recombinant CCL8 stimulation of NIH/3T3 fibroblasts, Western blot for collagen and p-ERK1/2, anti-CCL8 antibody treatment in LAT Y136F knockin mice","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanism with in vivo antibody blockade confirming fibrotic role; single study","pmids":["34391459"],"is_preprint":false},{"year":2022,"finding":"F. nucleatum induces CCL8 expression in macrophages via TLR4/NF-κB signaling; iron attenuates the inhibitory phosphorylation of NF-κB p65 by activating serine/threonine phosphatases, thereby augmenting F. nucleatum-induced CCL8 production in tumor-associated macrophages.","method":"Macrophage infection assay, TLR4/NF-κB pathway inhibition, iron supplementation/depletion, Western blot for p-p65","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection of signaling pathway with pharmacological and nutritional perturbations; single study","pmids":["36136589"],"is_preprint":false},{"year":2010,"finding":"Stromal cell-derived CCL8 cooperates with CXCL12 to attract hematopoietic progenitors that differentiate into regulatory dendritic cells; Leishmania donovani infection of bone marrow stromal cells enhances CCL8 production, increasing regulatory DC development.","method":"Murine leishmaniasis model, splenic stromal cell CCL8 production measurement, hematopoietic progenitor migration assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional migration and differentiation assay in infection context; single study","pmids":["20624948"],"is_preprint":false},{"year":2003,"finding":"Mouse orphan receptor L-CCR expressed in HEK293 cells responds to CCL2, CCL7, CCL8, and CCL5 with pertussis toxin-sensitive chemotaxis and Ca2+ transients; biotinylated CCL2 binds to L-CCR-expressing cells, identifying L-CCR as a functional receptor for CCL8.","method":"Receptor transfection in HEK293, chemotaxis assay, Ca2+ measurement, pertussis toxin inhibition, biotinylated ligand binding","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional receptor assay in transfected cells with multiple readouts; single study for mouse ortholog receptor","pmids":["12885941"],"is_preprint":false},{"year":2020,"finding":"CCL8 is upregulated in mast cells when co-cultured with endometrial cells; CCL8 promotes migration of endometrial epithelial and stromal cells and increases angiogenesis of endothelial cells; CCR1 (receptor for CCL8) is overexpressed in ectopic endometrium and co-localizes with blood vessels; CCR1 inhibition suppresses endometriosis development and angiogenesis in vivo.","method":"Mast cell-endometrial cell co-culture with mRNA sequencing, Transwell migration assay, CCK-8 proliferation, tube formation assay, mouse endometriosis model, CCR1 inhibition in vivo","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanism with in vivo validation; single study","pmids":["32768961"],"is_preprint":false},{"year":2021,"finding":"CCL8 deficiency in host mice receiving allogeneic bone marrow transplantation significantly reduces acute GVHD mortality (90% vs 23.4% survival), attenuates liver dysfunction and pathology, and is associated with a surge of plasma IL-6 in CCL8-/- recipients, suggesting CCL8 promotes GVHD pathogenesis potentially through IL-6 cascade.","method":"CCL8 knockout mice, allogeneic BMT model, survival analysis, histopathological scoring, cytokine ELISA","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with defined survival and pathological readout; single study","pmids":["34808257"],"is_preprint":false},{"year":2014,"finding":"Allergic airway inflammation decreases lung Klebsiella pneumoniae burden in a CCL8-dependent manner; neutralization of CCL8 reverses this protective effect, identifying a novel role for CCL8 in lung antibacterial immunity.","method":"Mouse allergic airway inflammation model, K. pneumoniae infection, CCL8 neutralizing antibody, bacterial burden measurement","journal":"Infection and immunity","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo neutralization with bacterial burden readout; single study","pmids":["24958709"],"is_preprint":false},{"year":2011,"finding":"Dendritic cells express CCL8 upon stimulation by allogeneic CD4+ T cells through MHC class II molecule interactions (cell-contact dependent); the early plasma CCL8 level (day 5) after allogeneic BMT correlates with GVHD survival and pathological scores.","method":"Dendritic cell-T cell co-culture, anti-MHC class II blocking, allogeneic BMT mouse model, CCL8 immunoassay","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro co-culture mechanistic study with in vivo correlation; single study","pmids":["21782767"],"is_preprint":false},{"year":2021,"finding":"CCL8 secreted by ECFCs induces IL-8 production in TNBC cells via c-Jun transcription factor; IL-8 reciprocally induces CCL8 in ECFCs, forming a positive feedback loop that promotes invasion, angiogenesis, and tumorigenicity of both cell types.","method":"Indirect co-culture, cytokine antibody array, RT-PCR, siRNA knockdown, xenograft model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — signaling defined with pathway inhibition/siRNA, c-Jun identified, in vivo xenograft confirmation; single study","pmids":["33833397"],"is_preprint":false},{"year":2025,"finding":"In myocardial infarction, P16+ senescent fibroblasts and macrophages are the main sources of CCL8; CCL8 recruits cytotoxic CD8+ T cells and NK cells to the infarcted heart, promoting cardiomyocyte apoptosis and adverse remodeling. CCL8 blockade or Ccl8 deletion in P16+ cells reduces CD8+ T cell infiltration and improves cardiac repair.","method":"p16-CreER reporter mice, dual-recombinase intersectional ablation, scRNA-seq, bulk RNA-seq, CCL8 neutralization antibody, CD8+ T cell depletion, CellChat intercellular communication analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models plus neutralization antibody, single-cell and bulk transcriptomics, defined cellular mechanism","pmids":["41766526"],"is_preprint":false},{"year":2024,"finding":"Muscle cell-derived (Pax7+, Myf5+, or MyoD+ myogenic progenitor cell) CCL8 negatively regulates myogenic differentiation; Cas9-mediated Ccl8 depletion in myogenic progenitor cells accelerates muscle regeneration after injury, and intramuscular recombinant CCL8 reverses this phenotype.","method":"Ccl8 knockdown in C2C12 myoblasts, AAV9-sgRNA Ccl8 gene editing in Pax7+/Myf5+/MyoD+ cells, barium chloride injury model, single-cell transcriptomics of existing datasets, recombinant CCL8 injection rescue","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — multiple myogenic lineage-specific KO models with functional rescue; single study","pmids":["39051762"],"is_preprint":false},{"year":2025,"finding":"In esophageal cancer, CBX6 promotes CCL8 expression by interacting with SMARCD1 to remodel chromatin at the CCL8 promoter; CCL8 secretion leads to CD8+ T cell exhaustion and tumor progression.","method":"Cbx6 knockdown, co-culture with CD8+ T cells, chromatin remodeling assay, tissue microarray, in vivo tumorigenesis","journal":"Cell biology and toxicology","confidence":"Low","confidence_rationale":"Tier 3 — chromatin remodeling mechanism inferred without direct ChIP for CCL8 promoter; single study","pmids":["41219497"],"is_preprint":false},{"year":2025,"finding":"HSP90 interacts with transcription factor STAT1 and stabilizes it, driving CCL8 expression; STAT1 knockdown attenuates CCL8 upregulation and macrophage recruitment in atrial cardiomyocytes, placing HSP90-STAT1-CCL8 in a pathway mediating atrial inflammation during hypertension-induced atrial fibrillation.","method":"RNA sequencing, HSP90 inhibitor 17AAG, STAT1 knockdown, AngII mouse AF model, HL-1 cell line experiments","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — STAT1 knockdown defining pathway in vitro and in vivo; single study","pmids":["41720180"],"is_preprint":false},{"year":2025,"finding":"USP18 stabilizes SOCS1 by inhibiting its ubiquitination and degradation, suppressing CCL8 production in alveolar type II epithelial cells through ERK-STAT3 signaling; USP18-deficient AT2 cells increase CCL8 expression, promoting Th2 cell and eosinophil recruitment; CCL8 knockdown in USP18 KO mice alleviates asthma symptoms.","method":"USP18 knockout mice, AT2-specific CCL8 knockdown, exogenous CCL8 treatment, SOCS1 ubiquitination assay, ERK-STAT3 pathway inhibition, Th2/eosinophil flow cytometry","journal":"Respiratory research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO + pathway mechanistic rescue experiments; single study","pmids":["41354823"],"is_preprint":false},{"year":2025,"finding":"JMJD1A (histone demethylase) cooperates with STAT1 to demethylate H3K9me2 on the IRF1 promoter, inducing IRF1 expression; IRF1 and JMJD1A together demethylate H3K9me2 on the CCL8 promoter to drive CCL8 expression in colonic epithelial cells, promoting macrophage and CD4+ T cell recruitment during enteric infection.","method":"JMJD1A-/- mice, C. rodentium infection, ChIP for H3K9me2, IRF1 overexpression/knockdown, macrophage depletion, mucosal immune cell analysis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP validation of epigenetic regulation at CCL8 promoter with genetic KO in vivo; single study","pmids":["41779805"],"is_preprint":false},{"year":2025,"finding":"miR-425 suppresses ZNF24 expression in astrocytes, which downregulates CCL8 secretion; reduced CCL8 leads to astrocyte activation that promotes breast cancer brain metastasis in vivo.","method":"miR-425 overexpression/inhibition in breast cancer EVs, astrocyte co-culture, ZNF24 knockdown, CCL8 ELISA, mouse brain metastasis model, immunohistochemistry","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic cascade validated in vitro and in vivo, miR-425-ZNF24-CCL8 axis confirmed; single study","pmids":["41977380"],"is_preprint":false}],"current_model":"CCL8 (MCP-2) is a CC chemokine that signals through multiple receptors (CCR1, CCR2, CCR3, CCR5, and in mice CCR8) via pertussis toxin-sensitive G-protein pathways to recruit monocytes, T lymphocytes, eosinophils, basophils, NK cells, and regulatory T cells; its transcription is driven by IFN-γ/IL-1β synergy through defined promoter elements (including STAT1/IRF1/JMJD1A-mediated chromatin remodeling), repressed by BLIMP1 and microRNAs (miR-146a, miR-92a), and its activity is modulated by extracellular proteolytic truncation (losing N-terminal residues) that converts the chemokine from an agonist to a CCR2 antagonist, while downstream it activates ERK, NF-κB, PI3K/AKT, and mTORC1 pathways in target cells to regulate inflammation, tumor microenvironment remodeling, tissue fibrosis, and host defense."},"narrative":{"teleology":[{"year":1992,"claim":"The identity of CCL8 as a distinct monocyte chemoattractant was unknown; its purification and sequencing established it as a novel CC chemokine structurally related to MCP-1 with selective monocyte-recruiting activity.","evidence":"Protein purification from osteosarcoma supernatants, peptide sequencing, Boyden chamber chemotaxis, intradermal injection in rabbits","pmids":["1613466"],"confidence":"High","gaps":["Receptor identity unknown","Mechanism of monocyte selectivity undefined","In vivo physiological role not tested"]},{"year":1994,"claim":"Whether CCL8 acted on cell types beyond monocytes was uncertain; demonstration that it attracts CD4+ and CD8+ T cells, eosinophils, and basophils via pertussis toxin-sensitive GPCRs and cross-desensitizes with MCP-1/RANTES receptors revealed it as a broad-spectrum chemoattractant with overlapping receptor usage.","evidence":"Boyden chamber chemotaxis, Ca2+ flux, pertussis toxin inhibition, cross-desensitization on T cells, eosinophils, and basophils","pmids":["7926371","7535823","7514401","7531149"],"confidence":"High","gaps":["Specific receptor identities not molecularly defined","Relative receptor preference hierarchy unknown"]},{"year":1997,"claim":"The molecular identity of CCL8 receptors was resolved by demonstrating direct high-affinity binding to CCR1 and CCR2B in transfected cells with functional chemotactic responses.","evidence":"Radioligand binding and chemotaxis in CCR1- and CCR2B-transfected HEK293 cells","pmids":["9115216"],"confidence":"High","gaps":["CCR3 and CCR5 interactions not yet characterized","In vivo receptor preference not determined"]},{"year":1998,"claim":"Whether CCL8 engaged CCR5 was unknown; binding and functional assays demonstrated high-affinity CCR5 agonism, HIV-1 gp120 competition, and preferential CCR5 use on activated T cells, expanding the receptor repertoire.","evidence":"Radioligand binding to CCR5 transfectants, gp120 competition, anti-CCR5 mAb blocking, chemotaxis","pmids":["9790730"],"confidence":"High","gaps":["CCR3 affinity not quantitated","Physiological relevance of HIV coreceptor blocking not tested in vivo"]},{"year":1999,"claim":"The transcriptional regulation of CCL8 was undefined; promoter deletion mapping identified an IFN-γ-responsive element between −340 and −301 and demonstrated synergistic induction by IFN-γ plus IL-1β.","evidence":"Luciferase reporter assays, EMSA in fibroblasts and osteosarcoma cells","pmids":["10496322"],"confidence":"High","gaps":["Specific transcription factors binding the element not identified","Post-transcriptional regulation unexplored"]},{"year":2008,"claim":"The signaling pathways controlling CCL8 mRNA accumulation were clarified: oncostatin M induces CCL8 via ERK1/2-driven c-Jun/c-Fos transcription and p38-mediated mRNA stabilization through tristetraprolin inhibition.","evidence":"MAPK inhibitors, siRNA knockdown of c-Jun/c-Fos, mRNA stability assays in dermal fibroblasts","pmids":["18981157"],"confidence":"High","gaps":["Whether this pathway operates in macrophages or other major CCL8 producers unknown","Direct tristetraprolin-CCL8 mRNA interaction not shown"]},{"year":2009,"claim":"A key question was whether CCL8 activity is modulated post-secretion; discovery that extracellular processing truncates CCL8(1–76) to CCL8(6–75), converting it from agonist to CCR2 antagonist, established a built-in negative feedback mechanism.","evidence":"N-terminal sequencing of truncated forms, Ca2+ and ERK signaling via CCR1/2/3/5 transfectants, chemotaxis, receptor internalization assays","pmids":["19224633"],"confidence":"High","gaps":["Identity of the responsible protease not determined","In vivo relevance of truncated form not demonstrated"]},{"year":2011,"claim":"Species-specific receptor usage was resolved when mouse CCL8 was shown to be a CCR8 agonist (not CCR2), recruiting Th2 cells to allergen-inflamed skin, with Ccl8−/− and Ccr8−/− mice showing reduced eosinophilic inflammation.","evidence":"Ccl8−/− and Ccr8−/− mouse atopic dermatitis models, adoptive transfer, receptor signaling assays","pmids":["21217759"],"confidence":"High","gaps":["Whether human CCL8 also signals through CCR8 not established","Structural basis for species-specific receptor selectivity unknown"]},{"year":2014,"claim":"Whether CCL8 transcription is tonically repressed was answered by showing BLIMP1 directly represses CCL8 in macrophages; Ccl8−/− mice demonstrated CCL8 recruits γ/δ T cells producing IL-17F for Listeria clearance.","evidence":"Conditional Blimp1 KO macrophages, transcriptome analysis, Ccl8−/− mice, Listeria infection, γ/δ T cell depletion","pmids":["24477914"],"confidence":"High","gaps":["BLIMP1 binding site on CCL8 promoter not mapped","Mechanism of γ/δ T cell chemotaxis to CCL8 (receptor identity) not defined"]},{"year":2014,"claim":"Post-transcriptional control of CCL8 by miRNAs was established: miR-146a targets CCL8 3′ UTR in microglia during HIV infection, and miR-92a suppression by HCMV LAcmvIL-10 de-represses CCL8 during viral latency.","evidence":"miRNA overexpression in primary microglial cells (PMID:20181935), secretome proteomics in myeloid progenitors (PMID:25253336)","pmids":["20181935","25253336"],"confidence":"Medium","gaps":["miR-146a direct luciferase validation for CCL8 not shown in the 2010 study","Quantitative contribution of miRNA regulation vs. transcriptional induction not compared"]},{"year":2018,"claim":"CCL8 was placed in visceral pain circuitry: spinal CCL8 acting through CCR5/ERK mediates colitis-induced hyperalgesia, and miR-146a-5p directly targets CCL8 3′ UTR (confirmed by dual-luciferase) to suppress this pathway.","evidence":"Dual-luciferase reporter assay, intrathecal CCL8 siRNA and miR-146a agomir, colorectal distension pain threshold in TNBS colitis model","pmids":["29550454","29037608"],"confidence":"Medium","gaps":["Cell type producing spinal CCL8 (neuron vs. glia) not definitively resolved","Whether CCL8/CCR5 pain signaling operates in humans unknown"]},{"year":2019,"claim":"CCL8's role in tumor immune microenvironments was mechanistically dissected: hypoxia-induced ZEB1 activates CCL8 transcription in cancer cells to recruit macrophages via CCR2/NF-κB, and miR-345-5p directly targets CCL8 3′ UTR to restrain pancreatic cancer NF-κB-driven proliferation.","evidence":"Macrophage migration assays, luciferase reporter for miR-345-5p, NF-κB pathway analysis in cervical and pancreatic cancer models","pmids":["31263103","30841468"],"confidence":"Medium","gaps":["Whether ZEB1 directly binds CCL8 promoter not shown by ChIP","NF-κB activation downstream of CCL8 lacks receptor specificity assignment"]},{"year":2021,"claim":"CCL8's pro-fibrotic function was established: CCL8 stimulates collagen production in fibroblasts via ERK1/2, and anti-CCL8 antibody reduces fibrosis in an IgG4-related disease model.","evidence":"Recombinant CCL8 stimulation, Western blot for collagen and p-ERK1/2, anti-CCL8 antibody in LAT Y136F knockin mice","pmids":["34391459"],"confidence":"Medium","gaps":["Receptor mediating fibrotic CCL8 signaling in fibroblasts not identified","Whether CCL8 drives fibrosis independently of immune cell recruitment not resolved"]},{"year":2022,"claim":"CCL8 was shown to drive a self-amplifying macrophage-monocyte recruitment loop in kidney allografts: donor macrophage CCL8 recruits recipient monocytes that differentiate and produce more CCL8, then recruit CCR8+ T cells; blocking CCL8-CCR8 reduces graft inflammation.","evidence":"Allogeneic murine kidney transplant, CCL8-CCR8 blocking antibody, macrophage depletion, flow cytometry","pmids":["35973731"],"confidence":"Medium","gaps":["Relative contribution of CCR2 vs. CCR8 in monocyte vs. T cell recruitment not dissected","Human relevance not tested"]},{"year":2023,"claim":"A tumor-metabolic axis for CCL8 was defined: lactate from tumor cells induces CCL8 in M2 macrophages via AKT/ERK, and CCL8 activates CCR5/mTORC1 on colorectal cancer cells to promote metastasis.","evidence":"RNA-seq, CCR5 knockdown/antagonist, allograft mouse model, colony formation and wound healing assays","pmids":["38136340"],"confidence":"Medium","gaps":["Whether mTORC1 is the direct effector or requires intermediate signaling steps unknown","Single study without independent replication"]},{"year":2025,"claim":"Epigenetic and transcriptional control of CCL8 was deepened: JMJD1A/STAT1/IRF1 demethylate H3K9me2 at the CCL8 promoter in colonic epithelium during infection; HSP90 stabilizes STAT1 to drive CCL8 in atrial cardiomyocytes; senescent cell-derived CCL8 recruits cytotoxic CD8+ T cells to infarcted hearts.","evidence":"JMJD1A−/− mice with ChIP at CCL8 promoter (PMID:41779805); HSP90 inhibitor/STAT1 knockdown in HL-1 cells (PMID:41720180); p16-CreER mice with CCL8 neutralization and CD8 depletion post-MI (PMID:41766526)","pmids":["41779805","41720180","41766526"],"confidence":"Medium","gaps":["Whether JMJD1A-IRF1 axis is specific to CCL8 or co-regulates other chemokines not tested","STAT1 vs. IRF1 hierarchy in different cell types not resolved","Therapeutic window for CCL8 blockade in cardiac repair unknown"]},{"year":null,"claim":"The identity of the protease that truncates CCL8(1–76) to the antagonist CCL8(6–75) in vivo remains unknown, as does the structural basis for species-specific receptor selectivity (human CCR1/2/3/5 vs. mouse CCR8); a comprehensive understanding of how CCL8 receptor choice is determined in different tissue microenvironments is lacking.","evidence":"","pmids":[],"confidence":"High","gaps":["Protease identity for N-terminal truncation not determined","Structural basis for mouse CCR8 vs. human CCR2 selectivity not resolved","No crystal structure of CCL8-receptor complex available"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,3,6,13]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,7,12]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,3,13,17,34,37]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,6,12,22,27,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,27,39]}],"complexes":[],"partners":["CCR1","CCR2","CCR5","CCR3","CCR8","STAT1","IRF1","BLIMP1"],"other_free_text":[]},"mechanistic_narrative":"CCL8 (MCP-2) is a CC chemokine that functions as a broad-spectrum leukocyte chemoattractant, orchestrating innate and adaptive immune cell recruitment in inflammation, infection, tissue repair, and tumor microenvironment remodeling. Originally isolated as a monocyte-selective chemoattractant [PMID:1613466], CCL8 signals through multiple CC chemokine receptors—CCR1, CCR2, CCR3, CCR5, and in mice CCR8—via pertussis toxin-sensitive G-protein pathways to recruit monocytes, T lymphocytes (CD4+, CD8+, γ/δ, Treg), eosinophils, basophils, NK cells, and hematopoietic progenitors [PMID:7926371, PMID:9115216, PMID:9790730, PMID:21217759, PMID:24477914, PMID:27471618]. CCL8 transcription is induced by IFN-γ (synergizing with IL-1β or TLR ligands) through a defined promoter region and is regulated by STAT1, IRF1, JMJD1A-mediated H3K9me2 demethylation at its promoter, ERK/p38 MAPK stabilization of its mRNA, and repressed by BLIMP1 and microRNAs (miR-146a, miR-92a, miR-345-5p) targeting its 3′ UTR [PMID:10496322, PMID:18981157, PMID:24477914, PMID:29550454, PMID:30841468, PMID:41779805]. Extracellular proteolytic truncation of full-length CCL8(1–76) to CCL8(6–75) converts it from an agonist to a CCR2-selective antagonist that blocks ERK signaling and induces receptor internalization, establishing a built-in negative regulatory mechanism [PMID:19224633]."},"prefetch_data":{"uniprot":{"accession":"P80075","full_name":"C-C motif chemokine 8","aliases":["HC14","Monocyte chemoattractant protein 2","Monocyte chemotactic protein 2","MCP-2","Small-inducible cytokine A8"],"length_aa":99,"mass_kda":11.2,"function":"Chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils. May play a role in neoplasia and inflammatory host responses. This protein can bind heparin. The processed form MCP-2(6-76) does not show monocyte chemotactic activity, but inhibits the chemotactic effect most predominantly of CCL7, and also of CCL2 and CCL5 and CCL8","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P80075/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL8","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL8","total_profiled":1310},"omim":[{"mim_id":"605643","title":"KALLIKREIN-RELATED PEPTIDASE 5; KLK5","url":"https://www.omim.org/entry/605643"},{"mim_id":"604828","title":"CHEMOKINE, C MOTIF, LIGAND 2; XCL2","url":"https://www.omim.org/entry/604828"},{"mim_id":"602283","title":"CHEMOKINE, CC MOTIF, LIGAND 8; CCL8","url":"https://www.omim.org/entry/602283"},{"mim_id":"600250","title":"CHEMOKINE, C MOTIF, LIGAND 1; XCL1","url":"https://www.omim.org/entry/600250"},{"mim_id":"256500","title":"NETHERTON SYNDROME; NETH","url":"https://www.omim.org/entry/256500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CCL8"},"hgnc":{"alias_symbol":["MCP-2","HC14"],"prev_symbol":["SCYA8"]},"alphafold":{"accession":"P80075","domains":[{"cath_id":"2.40.50.40","chopping":"45-99","consensus_level":"medium","plddt":95.8515,"start":45,"end":99}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P80075","model_url":"https://alphafold.ebi.ac.uk/files/AF-P80075-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P80075-F1-predicted_aligned_error_v6.png","plddt_mean":88.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL8","jax_strain_url":"https://www.jax.org/strain/search?query=CCL8"},"sequence":{"accession":"P80075","fasta_url":"https://rest.uniprot.org/uniprotkb/P80075.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P80075/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P80075"}},"corpus_meta":[{"pmid":"11023497","id":"PMC_11023497","title":"Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11023497","citation_count":546,"is_preprint":false},{"pmid":"1613466","id":"PMC_1613466","title":"Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1613466","citation_count":358,"is_preprint":false},{"pmid":"7926371","id":"PMC_7926371","title":"Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes.","date":"1994","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/7926371","citation_count":309,"is_preprint":false},{"pmid":"7531149","id":"PMC_7531149","title":"Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7531149","citation_count":308,"is_preprint":false},{"pmid":"9655469","id":"PMC_9655469","title":"MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study.","date":"1998","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9655469","citation_count":305,"is_preprint":false},{"pmid":"21217759","id":"PMC_21217759","title":"Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells.","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21217759","citation_count":257,"is_preprint":false},{"pmid":"18684849","id":"PMC_18684849","title":"Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.","date":"2008","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/18684849","citation_count":155,"is_preprint":false},{"pmid":"14647058","id":"PMC_14647058","title":"Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection.","date":"2003","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/14647058","citation_count":153,"is_preprint":false},{"pmid":"10502563","id":"PMC_10502563","title":"Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines.","date":"1999","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10502563","citation_count":122,"is_preprint":false},{"pmid":"9115216","id":"PMC_9115216","title":"Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9115216","citation_count":121,"is_preprint":false},{"pmid":"31263103","id":"PMC_31263103","title":"Hypoxia-induced ZEB1 promotes cervical cancer progression via CCL8-dependent tumour-associated macrophage recruitment.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31263103","citation_count":109,"is_preprint":false},{"pmid":"20181935","id":"PMC_20181935","title":"CCL8/MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20181935","citation_count":107,"is_preprint":false},{"pmid":"8189067","id":"PMC_8189067","title":"Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8189067","citation_count":107,"is_preprint":false},{"pmid":"19193208","id":"PMC_19193208","title":"IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay.","date":"2009","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/19193208","citation_count":100,"is_preprint":false},{"pmid":"15644410","id":"PMC_15644410","title":"TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15644410","citation_count":97,"is_preprint":false},{"pmid":"27471618","id":"PMC_27471618","title":"Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27471618","citation_count":93,"is_preprint":false},{"pmid":"7535823","id":"PMC_7535823","title":"Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7535823","citation_count":86,"is_preprint":false},{"pmid":"7514401","id":"PMC_7514401","title":"Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7514401","citation_count":79,"is_preprint":false},{"pmid":"27181207","id":"PMC_27181207","title":"A CCL8 gradient drives breast cancer cell dissemination.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27181207","citation_count":74,"is_preprint":false},{"pmid":"9790730","id":"PMC_9790730","title":"CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells.","date":"1998","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9790730","citation_count":65,"is_preprint":false},{"pmid":"18256320","id":"PMC_18256320","title":"CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18256320","citation_count":61,"is_preprint":false},{"pmid":"25253336","id":"PMC_25253336","title":"Latency-associated viral interleukin-10 (IL-10) encoded by human cytomegalovirus modulates cellular IL-10 and CCL8 Secretion during latent infection through changes in the cellular microRNA hsa-miR-92a.","date":"2014","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/25253336","citation_count":58,"is_preprint":false},{"pmid":"19224633","id":"PMC_19224633","title":"Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19224633","citation_count":58,"is_preprint":false},{"pmid":"30841468","id":"PMC_30841468","title":"MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30841468","citation_count":55,"is_preprint":false},{"pmid":"26320180","id":"PMC_26320180","title":"The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26320180","citation_count":42,"is_preprint":false},{"pmid":"28057004","id":"PMC_28057004","title":"Gene profile of fibroblasts identify relation of CCL8 with idiopathic pulmonary fibrosis.","date":"2017","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/28057004","citation_count":40,"is_preprint":false},{"pmid":"12885941","id":"PMC_12885941","title":"Expression of L-CCR in HEK 293 cells reveals functional responses to CCL2, CCL5, CCL7, and CCL8.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12885941","citation_count":40,"is_preprint":false},{"pmid":"32768961","id":"PMC_32768961","title":"Possible involvement of crosstalk between endometrial cells and mast cells in the development of endometriosis via CCL8/CCR1.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32768961","citation_count":38,"is_preprint":false},{"pmid":"4051325","id":"PMC_4051325","title":"Newborn rabbit alveolar macrophages are deficient in two microbicidal cationic peptides, MCP-1 and MCP-2.","date":"1985","source":"The American review of respiratory disease","url":"https://pubmed.ncbi.nlm.nih.gov/4051325","citation_count":36,"is_preprint":false},{"pmid":"9119400","id":"PMC_9119400","title":"The human MCP-2 gene (SCYA8): cloning, sequence analysis, tissue expression, and assignment to the CC chemokine gene contig on chromosome 17q11.2.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9119400","citation_count":34,"is_preprint":false},{"pmid":"32535027","id":"PMC_32535027","title":"CCL8 Promotes Postpartum Breast Cancer by Recruiting M2 Macrophages.","date":"2020","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/32535027","citation_count":34,"is_preprint":false},{"pmid":"7780043","id":"PMC_7780043","title":"Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines.","date":"1995","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/7780043","citation_count":34,"is_preprint":false},{"pmid":"16988274","id":"PMC_16988274","title":"Cytokine and chemokine transcription profile during Mycoplasma pulmonis infection in susceptible and resistant strains of mice: macrophage inflammatory protein 1beta (CCL4) and monocyte chemoattractant protein 2 (CCL8) and accumulation of CCR5+ Th cells.","date":"2006","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16988274","citation_count":33,"is_preprint":false},{"pmid":"9199875","id":"PMC_9199875","title":"Induction of gelatinase B and MCP-2 in baboons during sublethal and lethal bacteraemia.","date":"1997","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/9199875","citation_count":32,"is_preprint":false},{"pmid":"29281969","id":"PMC_29281969","title":"Functional expression of CCL8 and its interaction with chemokine receptor CCR3.","date":"2017","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29281969","citation_count":31,"is_preprint":false},{"pmid":"4091528","id":"PMC_4091528","title":"Cytotoxicity of rabbit macrophage peptides MCP-1 and MCP-2 for mouse tumor cells.","date":"1985","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/4091528","citation_count":31,"is_preprint":false},{"pmid":"24477914","id":"PMC_24477914","title":"The transcriptional repressor BLIMP1 curbs host defenses by suppressing expression of the chemokine CCL8.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24477914","citation_count":30,"is_preprint":false},{"pmid":"36672151","id":"PMC_36672151","title":"Pathogenic Th2 Cytokine Profile Skewing by IFN-γ-Responding Vitiligo Fibroblasts via CCL2/CCL8.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36672151","citation_count":28,"is_preprint":false},{"pmid":"29037608","id":"PMC_29037608","title":"Chemokine CCL8 and its receptor CCR5 in the spinal cord are involved in visceral pain induced by experimental colitis in mice.","date":"2017","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/29037608","citation_count":28,"is_preprint":false},{"pmid":"23418602","id":"PMC_23418602","title":"Induction of CCL8/MCP-2 by mycobacteria through the activation of TLR2/PI3K/Akt signaling pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23418602","citation_count":28,"is_preprint":false},{"pmid":"18981157","id":"PMC_18981157","title":"Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18981157","citation_count":28,"is_preprint":false},{"pmid":"24958709","id":"PMC_24958709","title":"Allergic airway inflammation decreases lung bacterial burden following acute Klebsiella pneumoniae infection in a neutrophil- and CCL8-dependent manner.","date":"2014","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24958709","citation_count":27,"is_preprint":false},{"pmid":"38136340","id":"PMC_38136340","title":"Lactate-Induced CCL8 in Tumor-Associated Macrophages Accelerates the Progression of Colorectal Cancer through the CCL8/CCR5/mTORC1 Axis.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38136340","citation_count":25,"is_preprint":false},{"pmid":"30902794","id":"PMC_30902794","title":"CCL8 enhances sensitivity of cutaneous squamous cell carcinoma to photodynamic therapy by recruiting M1 macrophages.","date":"2019","source":"Photodiagnosis and photodynamic therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30902794","citation_count":24,"is_preprint":false},{"pmid":"29339207","id":"PMC_29339207","title":"Nicaraven reduces cancer metastasis to irradiated lungs by decreasing CCL8 and macrophage recruitment.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29339207","citation_count":24,"is_preprint":false},{"pmid":"11044560","id":"PMC_11044560","title":"Cloning of equine chemokines eotaxin, monocyte chemoattractant protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and induction by IL-4 in dermal fibroblasts.","date":"2000","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11044560","citation_count":24,"is_preprint":false},{"pmid":"36136589","id":"PMC_36136589","title":"Iron accelerates Fusobacterium nucleatum-induced CCL8 expression in macrophages and is associated with colorectal cancer progression.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36136589","citation_count":23,"is_preprint":false},{"pmid":"20624948","id":"PMC_20624948","title":"Stromal cell-derived CXCL12 and CCL8 cooperate to support increased development of regulatory dendritic cells following Leishmania infection.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20624948","citation_count":23,"is_preprint":false},{"pmid":"23584443","id":"PMC_23584443","title":"Monitoring of TNFR1, IL-2Rα, HGF, CCL8, IL-8 and IL-12p70 following HSCT and their role as GVHD biomarkers in paediatric patients.","date":"2013","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/23584443","citation_count":23,"is_preprint":false},{"pmid":"33833397","id":"PMC_33833397","title":"CCL8 mediates crosstalk between endothelial colony forming cells and triple-negative breast cancer cells through IL-8, aggravating invasion and tumorigenicity.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33833397","citation_count":21,"is_preprint":false},{"pmid":"35973731","id":"PMC_35973731","title":"Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function.","date":"2022","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/35973731","citation_count":21,"is_preprint":false},{"pmid":"11164897","id":"PMC_11164897","title":"Expression of the chemokines, monocyte chemotactic protein (MCP)-1 and MCP-2 in endometrium of normal women and Norplant users, does not support a central role in macrophage infiltration into endometrium.","date":"2001","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11164897","citation_count":21,"is_preprint":false},{"pmid":"38528587","id":"PMC_38528587","title":"Single-cell RNA sequencing reveals recruitment of the M2-like CCL8high macrophages in Lewis lung carcinoma-bearing mice following hypofractionated radiotherapy.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38528587","citation_count":19,"is_preprint":false},{"pmid":"25764912","id":"PMC_25764912","title":"CCL8 and the Immune Control of Cytomegalovirus in Organ Transplant Recipients.","date":"2015","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/25764912","citation_count":17,"is_preprint":false},{"pmid":"29550454","id":"PMC_29550454","title":"MicroRNA-146a-5p attenuates visceral hypersensitivity through targeting chemokine CCL8 in the spinal cord in a mouse model of colitis.","date":"2018","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/29550454","citation_count":16,"is_preprint":false},{"pmid":"31423262","id":"PMC_31423262","title":"MicroRNA-181 inhibits glioblastoma cell growth by directly targeting CCL8.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31423262","citation_count":14,"is_preprint":false},{"pmid":"21782767","id":"PMC_21782767","title":"Early expression of plasma CCL8 closely correlates with survival rate of acute graft-vs.-host disease in mice.","date":"2011","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21782767","citation_count":14,"is_preprint":false},{"pmid":"32498476","id":"PMC_32498476","title":"CaSR Antagonist (Calcilytic) NPS 2143 Hinders the Release of Neuroinflammatory IL-6, Soluble ICAM-1, RANTES, and MCP-2 from Aβ-Exposed Human Cortical Astrocytes.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32498476","citation_count":14,"is_preprint":false},{"pmid":"10496322","id":"PMC_10496322","title":"Transcriptional control of the human MCP-2 gene promoter by IFN-gamma and IL-1beta in connective tissue cells.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10496322","citation_count":14,"is_preprint":false},{"pmid":"22894773","id":"PMC_22894773","title":"Pseudogenization of the MCP-2/CCL8 chemokine gene in European rabbit (genus Oryctolagus), but not in species of Cottontail rabbit (Sylvilagus) and Hare (Lepus).","date":"2012","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22894773","citation_count":13,"is_preprint":false},{"pmid":"34391459","id":"PMC_34391459","title":"Pathogenic roles and therapeutic potential of the CCL8-CCR8 axis in a murine model of IgG4-related sialadenitis.","date":"2021","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34391459","citation_count":12,"is_preprint":false},{"pmid":"7999015","id":"PMC_7999015","title":"Porcine luteal cells express monocyte chemoattractant protein-2 (MCP-2): analysis by cDNA cloning and northern analysis.","date":"1994","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7999015","citation_count":12,"is_preprint":false},{"pmid":"36404927","id":"PMC_36404927","title":"Beneficial effects of CCL8 inhibition at lipopolysaccharide-induced lung injury.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36404927","citation_count":11,"is_preprint":false},{"pmid":"32307587","id":"PMC_32307587","title":"Evaluation of the inflammatory markers CCL8, CXCL5, and LIF in patients with anastomotic leakage after colorectal cancer surgery.","date":"2020","source":"International journal of colorectal disease","url":"https://pubmed.ncbi.nlm.nih.gov/32307587","citation_count":9,"is_preprint":false},{"pmid":"19302923","id":"PMC_19302923","title":"Upregulation of plasma CCL8 in mouse model of graft-vs-host disease.","date":"2009","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/19302923","citation_count":9,"is_preprint":false},{"pmid":"40541814","id":"PMC_40541814","title":"Insights on the role of the chemokine CCL8 in pathology.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40541814","citation_count":8,"is_preprint":false},{"pmid":"22987449","id":"PMC_22987449","title":"Janus kinase 2 and signal transducer and activator of transcription 3 activation is not essential for CCL3-, CCL5- or CCL8-induced chemotaxis.","date":"2012","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/22987449","citation_count":8,"is_preprint":false},{"pmid":"37567910","id":"PMC_37567910","title":"Mesenchymal stem cells enhance CCL8 expression by podocytes in lupus-prone MRL.Faslpr mice.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37567910","citation_count":7,"is_preprint":false},{"pmid":"39774471","id":"PMC_39774471","title":"Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice.","date":"2025","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/39774471","citation_count":6,"is_preprint":false},{"pmid":"27306379","id":"PMC_27306379","title":"Adaptive Gene Loss? Tracing Back the Pseudogenization of the Rabbit CCL8 Chemokine.","date":"2016","source":"Journal of molecular evolution","url":"https://pubmed.ncbi.nlm.nih.gov/27306379","citation_count":6,"is_preprint":false},{"pmid":"34808257","id":"PMC_34808257","title":"CCL8 deficiency in the host abrogates early mortality of acute graft-versus-host disease in mice with dysregulated IL-6 expression.","date":"2021","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/34808257","citation_count":6,"is_preprint":false},{"pmid":"34788319","id":"PMC_34788319","title":"Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn's disease.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34788319","citation_count":6,"is_preprint":false},{"pmid":"19415413","id":"PMC_19415413","title":"CCL8/MCP-2 association analysis in patients with Alzheimer's disease and frontotemporal lobar degeneration.","date":"2009","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19415413","citation_count":6,"is_preprint":false},{"pmid":"30663558","id":"PMC_30663558","title":"Diagnostic Accuracy of Monocyte Chemotactic Protein (MCP)-2 as Biomarker in Response to PE35/PPE68 Proteins: A Promising Diagnostic Method for the Discrimination of Active and Latent Tuberculosis.","date":"2019","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/30663558","citation_count":5,"is_preprint":false},{"pmid":"35344629","id":"PMC_35344629","title":"Dexamethasone attenuated thoracic aortic aneurysm and dissection in vascular smooth muscle cell Tgfbr2-disrupted mice with CCL8 suppression.","date":"2022","source":"Experimental physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35344629","citation_count":4,"is_preprint":false},{"pmid":"37532728","id":"PMC_37532728","title":"Identification of potent anti-Candida metabolites produced by the soft coral associated Streptomyces sp. HC14 using chemoinformatics.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37532728","citation_count":4,"is_preprint":false},{"pmid":"40545574","id":"PMC_40545574","title":"Chimeric diphtheria toxin-CCL8 cytotoxic peptide for breast cancer management.","date":"2025","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40545574","citation_count":4,"is_preprint":false},{"pmid":"39051762","id":"PMC_39051762","title":"Muscle cell-derived Ccl8 is a negative regulator of skeletal muscle regeneration.","date":"2024","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/39051762","citation_count":3,"is_preprint":false},{"pmid":"32432500","id":"PMC_32432500","title":"Silencing CCL8 inhibited the proliferation and migration of PDGF-BB-stimulated human aortic smooth muscle cells.","date":"2020","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32432500","citation_count":3,"is_preprint":false},{"pmid":"36628560","id":"PMC_36628560","title":"CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC).","date":"2023","source":"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia","url":"https://pubmed.ncbi.nlm.nih.gov/36628560","citation_count":3,"is_preprint":false},{"pmid":"33902378","id":"PMC_33902378","title":"Association between the Genetic Polymorphisms of CCL2, CCL5, CCL8, CCR2, and CCR5 with Chronic Hepatitis C Virus Infection in the Chinese Han Population.","date":"2021","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/33902378","citation_count":3,"is_preprint":false},{"pmid":"41251087","id":"PMC_41251087","title":"Spatiotemporal mapping reveals Ccl8hi macrophages as key drivers of testicular inflammaging.","date":"2025","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41251087","citation_count":2,"is_preprint":false},{"pmid":"40685774","id":"PMC_40685774","title":"Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling.","date":"2025","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/40685774","citation_count":2,"is_preprint":false},{"pmid":"34160019","id":"PMC_34160019","title":"Revisiting CCL-type chemokines in breast cancer and its milieu: prominent targetable chemokines, CCL8 and CCL21.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/34160019","citation_count":2,"is_preprint":false},{"pmid":"38889138","id":"PMC_38889138","title":"Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.","date":"2024","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/38889138","citation_count":2,"is_preprint":false},{"pmid":"41155258","id":"PMC_41155258","title":"Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41155258","citation_count":1,"is_preprint":false},{"pmid":"41318072","id":"PMC_41318072","title":"Role of CCL8 in cancer immunity and tumor progression: Implications for cancer treatment.","date":"2025","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41318072","citation_count":0,"is_preprint":false},{"pmid":"41354823","id":"PMC_41354823","title":"USP18 confers protection against allergic asthma by suppressing CCL8 production in alveolar type II epithelial cells.","date":"2025","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/41354823","citation_count":0,"is_preprint":false},{"pmid":"41408455","id":"PMC_41408455","title":"CCL8 suppresses ovarian cancer progression via M1 macrophage polarization and NF-κB-mediated apoptosis.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41408455","citation_count":0,"is_preprint":false},{"pmid":"41766526","id":"PMC_41766526","title":"P16+ Cells Drive Adverse Postischemic Cardiac Remodeling Through CCL8-Mediated Recruitment of Cytotoxic Lymphocytes.","date":"2026","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/41766526","citation_count":0,"is_preprint":false},{"pmid":"41720180","id":"PMC_41720180","title":"Targeting HSP90 suppresses STAT1/CCL8-driven inflammation and mitigates mitochondrial dysfunction to attenuate hypertension-induced atrial fibrillation.","date":"2026","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41720180","citation_count":0,"is_preprint":false},{"pmid":"41779805","id":"PMC_41779805","title":"Histone demethylase JMJD1A protects mice from enteric bacterial infection by upregulating CCL8 expression to recruit macrophages and CD4+ T cells.","date":"2026","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/41779805","citation_count":0,"is_preprint":false},{"pmid":"40661472","id":"PMC_40661472","title":"Extracellular vesicle-derived miR-425-5p (miR-425) activates astrocytes in the brain to promote breast cancer brain metastasis via the novel miR-425-ZNF24-CCL8 signaling axis.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40661472","citation_count":0,"is_preprint":false},{"pmid":"41977380","id":"PMC_41977380","title":"Breast Cancer-Derived Extracellular Vesicle miR-425-5p (miR-425) Promotes Brain Metastasis via Activating Astrocytes Through the Novel miR-425-ZNF24-CCL8 Signaling Axis.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41977380","citation_count":0,"is_preprint":false},{"pmid":"41219497","id":"PMC_41219497","title":"CBX6 induces CD8+ T cell exhaustion and tumor development in esophageal squamous cell carcinoma through SMARCD1-mediated CCL8 secretion and lactate efflux.","date":"2025","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/41219497","citation_count":0,"is_preprint":false},{"pmid":"41843172","id":"PMC_41843172","title":"CCL8-dependent recruitment of natural killer cells enhances the antitumor activity of neoadjuvant chemotherapy in gastric cancer.","date":"2026","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/41843172","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.08.681192","title":"Causal Modeling Reveals Cell-Cell Communication Dynamics in the Tumor Microenvironment During Anti-PD-1 Therapy in Breast Cancer Patients","date":"2025-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.08.681192","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.19.670635","title":"A Spatially Coordinated Keratinocyte-Fibroblast Circuit Recruits MMP9<sup>+</sup> Myeloid Cells to Drive IFN-I-Driven Inflammation in Photosensitive Autoimmunity","date":"2025-08-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.19.670635","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.13.24313599","title":"A multi-omics bidirectional mendelian randomization study and meta-analysis on the causal relationship between gut microbiota, inflammatory proteins, and fibromyalgia.","date":"2024-09-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.13.24313599","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.13.24310337","title":"Altered Cytokine Profile in Clinically Suspected Seronegative Autoimmune Associated Epilepsy","date":"2024-09-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.13.24310337","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53535,"output_tokens":10185,"usd":0.15669},"stage2":{"model":"claude-opus-4-6","input_tokens":14160,"output_tokens":4217,"usd":0.264338},"total_usd":0.421028,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CCL8 (MCP-2) was isolated and characterized as a novel CC chemokine that specifically attracts monocytes but not neutrophils in vitro and in vivo, with a primary structure closely related to MCP-1, establishing it as a monocyte chemoattractant.\",\n      \"method\": \"Protein purification, peptide sequencing, Boyden chamber chemotaxis assay, intradermal injection in rabbits\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original isolation with sequencing and functional chemotaxis assay, foundational paper with 358 citations\",\n      \"pmids\": [\"1613466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCL8 (MCP-2) uses CCR1 and CCR2B as its functional receptors, as demonstrated by radioiodinated MCP-2 binding to CCR1- and CCR2B-transfected HEK293 cells, competitive displacement, and chemotaxis of transfected cells.\",\n      \"method\": \"Radioligand binding assay, receptor-transfected cell chemotaxis, competitive displacement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding assay with receptor-transfected cells plus functional chemotaxis, replicated by multiple labs\",\n      \"pmids\": [\"9115216\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CCL8 (MCP-2) attracts human CD4+ and CD8+ T lymphocytes, induces Ca2+ flux via pertussis toxin-sensitive G-protein-coupled receptors, and shares receptors with MCP-1 and MCP-3 as shown by cross-desensitization experiments.\",\n      \"method\": \"Boyden chamber chemotaxis, cytosolic Ca2+ measurement, pertussis toxin treatment, receptor desensitization assay\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (chemotaxis, Ca2+ flux, desensitization), 309 citations\",\n      \"pmids\": [\"7926371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL8 (MCP-2) activates human basophils and eosinophils, inducing Ca2+ transients, chemotaxis, and mediator release. Cross-desensitization showed CCL8 interacts with receptors for both MCP-1 and RANTES. In IL-3-untreated basophils, MCP-2 acts as a functional inhibitor of CC chemokine actions.\",\n      \"method\": \"Basophil/eosinophil activation assay, Ca2+ measurement, chemotaxis, receptor desensitization\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with desensitization controls, 86 citations\",\n      \"pmids\": [\"7535823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CCL8 (MCP-2) acts on human monocytes to induce migration and N-acetyl-beta-D-glucosaminidase release. Cross-desensitization and competitive binding studies showed MCP-2 shares receptors with MCP-1, MCP-3 and also interacts with RANTES/MIP-1 receptors, but not vice versa.\",\n      \"method\": \"Monocyte migration assay, enzyme release assay, Ca2+ measurement, radiolabeled MCP-1 and MIP-1alpha binding competition\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with receptor binding competition, 308 citations\",\n      \"pmids\": [\"7531149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CCL8 (MCP-2) attracts human eosinophils and cross-desensitizes eosinophil chemotaxis towards RANTES, suggesting CCL8 signals through the RANTES receptor on eosinophils.\",\n      \"method\": \"Boyden chamber eosinophil chemotaxis, cross-desensitization experiments\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with cross-desensitization, single study\",\n      \"pmids\": [\"7514401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCL8 (MCP-2) binds CCR5 with high affinity, acts as a true CCR5 agonist eliciting chemotaxis and Ca2+ flux in CCR5 transfectants, blocks HIV-1 gp120 binding to CCR5, and preferentially uses CCR5 (over CCR1 or CCR2) on activated T cells.\",\n      \"method\": \"Radioligand binding to CCR5 transfectants, chemotaxis assay, Ca2+ flux, gp120 competition assay, anti-CCR5 mAb blocking\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution with transfected receptors, multiple orthogonal assays, functional validation\",\n      \"pmids\": [\"9790730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CCL8 (MCP-2) is chemically synthesized into a biologically active 76-residue chemokine with correct disulfide bridges, is chemotactic for monocytes at ~7.5 ng/ml (comparable to natural MCP-2), and does not induce neutrophil chemotaxis.\",\n      \"method\": \"Chemical synthesis (Fmoc chemistry), RP-HPLC purification, SDS-PAGE, disulfide bridge formation, monocyte chemotaxis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with functional validation; confirmed that monocyte selectivity is intrinsic to the chemokine structure\",\n      \"pmids\": [\"8189067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Synthetic CCL8 (MCP-2) co-elutes and co-migrates with natural MCP-2, has monocyte chemotactic activity at 7.5 ng/ml, and does not attract neutrophils, confirming that the 76-residue folded structure is sufficient for biological activity.\",\n      \"method\": \"Chemical synthesis, RP-HPLC, SDS-PAGE, monocyte and neutrophil chemotaxis\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of chemokine from synthetic peptide with functional assay\",\n      \"pmids\": [\"7780043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The CCL8 gene (SCYA8) was cloned from chromosome 17q11.2, has a conserved three-exon/two-intron structure shared with MCP-1 and MCP-3, and produces a 1.0-kb mRNA predominantly in small intestine, peripheral blood, heart, placenta, lung, skeletal muscle, ovary, colon, and spinal cord.\",\n      \"method\": \"YAC contig PCR cloning, gene sequencing, Northern blot analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing and Northern blot confirming gene structure and expression pattern\",\n      \"pmids\": [\"9119400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IFN-gamma induces CCL8 (MCP-2) transcription in fibroblasts through a promoter region between -340 and -301 (relative to transcription start), containing elements recognized by transcription factors identified by EMSA; IL-1beta alone was insufficient but synergized with IFN-gamma for additional induction.\",\n      \"method\": \"Promoter deletion/luciferase reporter assay, electrophoretic mobility shift assay (EMSA), transfection into diploid fibroblasts and osteosarcoma cells\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter deletion mapping with luciferase and EMSA in two cell types\",\n      \"pmids\": [\"10496322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MMP-9 (gelatinase B) does not cleave CCL8 (RANTES and MCP-2 are left intact by gelatinase B), in contrast to its processing of IL-8 and degradation of CTAP-III, PF-4, and GRO-alpha.\",\n      \"method\": \"In vitro protease cleavage assay with purified MMP-9 and chemokines, functional neutrophil activation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assay with purified proteins; 546 citations\",\n      \"pmids\": [\"11023497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL8 (MCP-2) is synergistically induced by combined IFN-gamma + IL-1beta (or IFN-gamma + TLR ligands) in fibroblasts and endothelial cells. The intact CCL8(1-76) is processed into CCL8(6-75) by an extracellular protease, losing chemotactic activity but retaining receptor occupancy and acting as a CCR2 antagonist that inhibits MCP-1/CCL2 and MCP-2 ERK signaling and induces CCR2 internalization.\",\n      \"method\": \"Cytokine induction assay, N-terminal sequencing of truncated forms, Ca2+ signaling via CCR1/2/3/5-transfected cells, ERK signaling, chemotaxis assay, receptor internalization\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical characterization of natural truncation, functional receptor assays with multiple orthogonal endpoints\",\n      \"pmids\": [\"19224633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mouse CCL8 is an agonist for CCR8 (but not CCR2), recruiting IL-5-enriched CCR8+ Th2 cells to allergen-inflamed skin. Ccr8- and Ccl8-deficient mice had markedly reduced eosinophilic inflammation in an atopic dermatitis model, and adoptive transfer confirmed CCR8 as key for Th2 cell skin recruitment.\",\n      \"method\": \"CCR8/CCR2 signaling assay, Ccl8-/- and Ccr8-/- mouse models, adoptive transfer, chronic atopic dermatitis model, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple knockout models plus receptor specificity assays and adoptive transfer; 257 citations\",\n      \"pmids\": [\"21217759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL8/MCP-2 is a direct target of miR-146a in HIV-1-infected human microglial cells; overexpression of miR-146a prevented HIV-induced CCL8 secretion, consistent with miR-146a binding the CCL8 3' UTR.\",\n      \"method\": \"miRNA overexpression in primary microglial cells, ELISA for CCL8, HIV-1 infection model, analysis of HIVE brain samples\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — overexpression/knockdown with functional readout but lacks explicit luciferase reporter for miR-146a targeting CCL8 3' UTR in this paper\",\n      \"pmids\": [\"20181935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The viral HCMV protein LAcmvIL-10 suppresses cellular miRNA hsa-miR-92a, which directly targets the CCL8 3' UTR; loss of hsa-miR-92a de-represses CCL8, increasing its secretion during HCMV latent infection of myeloid progenitor cells.\",\n      \"method\": \"Primary myeloid progenitor cell latency model, miRNA analysis, secretome proteomics, functional linkage of LAcmvIL-10 to miR-92a to CCL8\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic chain from viral protein to miRNA to CCL8 in primary cells, single study\",\n      \"pmids\": [\"25253336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Mycobacterium infection induces CCL8/MCP-2 production in macrophages through TLR2/PI3K/Akt and p38 signaling pathways; CCL8 accumulates in TB pleural effusions and its primary receptor CCR5 is expressed on pleural CD4+ T cells.\",\n      \"method\": \"BCG and M. tuberculosis infection of macrophage cell lines and primary MDMs, signaling inhibitor studies, protein array, qPCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway identified by pharmacological inhibitors with multiple cell types, single study\",\n      \"pmids\": [\"23418602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BLIMP1 directly represses CCL8 transcription in macrophages. BLIMP1-deficient macrophages express elevated CCL8; CCL8 is chemotactic for γ/δ T cells enriched for IL-17F, and CCL8-mediated Listeria clearance is dependent on γ/δ T cells.\",\n      \"method\": \"Conditional Blimp1 KO macrophages, transcriptome analysis, Ccl8-/- mice, Listeria monocytogenes infection model, γ/δ T cell depletion\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with transcriptome analysis plus Ccl8 KO and T cell depletion establishing pathway position\",\n      \"pmids\": [\"24477914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Oncostatin M stimulates CCL8 expression in primary human dermal fibroblasts via ERK1/2 and p38 MAPK pathways (through c-Jun and c-Fos as ERK targets); p38 prolongs CCL8 mRNA half-life by inhibiting tristetraprolin. CCL8 is not regulated by STAT1, STAT3, or STAT5, but STAT5/CIS axis selectively represses CCL1 (not CCL8).\",\n      \"method\": \"Cytokine stimulation, MAPK inhibitors, siRNA knockdown of c-Jun/c-Fos/STATs, mRNA stability assays, migration assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors and siRNA knockdowns defining signaling pathway, multiple orthogonal endpoints\",\n      \"pmids\": [\"18981157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL8 interacts with CCR3 with a dissociation constant of ~1.2 × 10^-7 M measured by quartz crystal microbalance; CCL8 induces CCR3 internalization in vivo within 1 hour and elicits weaker chemotaxis of CCR3-expressing cells compared to CCL11 and CCL24.\",\n      \"method\": \"Quartz crystal microbalance (QCM) binding assay, CCR3 internalization assay, transwell chemotaxis assay\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — direct in vitro binding measurement plus cellular functional assays, single study\",\n      \"pmids\": [\"29281969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TRAIL pretreatment abrogates TNF-alpha-induced CCL8 and CXCL10 upregulation in endothelial cells via TRAIL-R1 and TRAIL-R2, and exogenous CCL8 plus CXCL10 restores the proadhesive activity of TNF-alpha, establishing that CCL8 is a key mediator of TNF-alpha-induced leukocyte adhesion to endothelium.\",\n      \"method\": \"cDNA microarray, neutralizing antibody rescue experiments, agonistic anti-TRAIL receptor antibodies, HL-60 adhesion assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — microarray plus gain-of-function rescue identifies CCL8 as effector; single study\",\n      \"pmids\": [\"15644410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL8 drives Treg recruitment to metastatic lungs via CCR5 signaling; F4/80+ macrophages in metastatic lungs produce CCL8, Tregs in metastatic lungs are enriched for CCR5, and Maraviroc (CCR5 inhibitor) reduces CCL8-driven Treg migration ex vivo and reduces metastatic tumor burden in vivo.\",\n      \"method\": \"Flow cytometry, ex vivo Treg migration toward CCL8, CCR5 inhibitor treatment, metastatic mouse tumor model\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional migration assay with pharmacological inhibition and in vivo model; single study\",\n      \"pmids\": [\"27471618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Hypoxia-induced ZEB1 in cervical cancer cells activates CCL8 transcription, which then attracts macrophages via the CCR2-NF-κB pathway, promoting tumor-associated macrophage accumulation and cancer progression.\",\n      \"method\": \"In vitro macrophage migration assay, chemokine expression array, mechanistic follow-up of ZEB1-CCL8-CCR2 axis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway mechanistically defined in vitro with migration assay and NF-κB pathway; single study\",\n      \"pmids\": [\"31263103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-345-5p directly targets the CCL8 3' UTR (confirmed by luciferase assay), suppressing CCL8 expression; CCL8 activates NF-κB signaling to promote pancreatic cancer cell proliferation and invasion.\",\n      \"method\": \"Luciferase reporter assay, Western blot, Transwell invasion, NF-κB pathway analysis\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct luciferase confirmation of miRNA targeting plus pathway analysis; single study\",\n      \"pmids\": [\"30841468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-146a-5p directly targets the 3' UTR of CCL8 (confirmed by dual-luciferase reporter assay) in spinal neurons; CCL8 upregulation in the spinal cord mediates visceral pain via CCR5/ERK activation, and intrathecal CCL8 siRNA or miR-146a-5p agomir reduces colitis-induced visceral hyperalgesia.\",\n      \"method\": \"Dual-luciferase reporter assay, intrathecal injection, siRNA knockdown, neutralizing antibody, colorectal distension pain threshold measurement\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — validated 3' UTR target with in vivo loss-of-function rescue; single study\",\n      \"pmids\": [\"29550454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CCL8 and its receptor CCR5 are upregulated in the spinal cord following colitis (TNBS model); intrathecal CCL8 neutralizing antibody or CCR5 antagonist reduces visceral hyperalgesia and spinal ERK activation, placing CCL8/CCR5/ERK in a visceral pain signaling pathway.\",\n      \"method\": \"TNBS colitis mouse model, intrathecal antibody/antagonist injection, ERK phosphorylation assay, MEK inhibitor treatment, pain behavioral testing\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with defined signaling endpoint; single study\",\n      \"pmids\": [\"29037608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In a murine kidney transplant model, donor kidney resident macrophages upregulate CCL8 post-transplant, which promotes recipient monocyte graft infiltration, monocyte differentiation to resident macrophages (further expressing CCL8), and subsequent CCR8+ T cell infiltration; blocking CCL8-CCR8 or depleting donor macrophages reduces early allograft inflammation and improves graft function.\",\n      \"method\": \"Allogeneic murine kidney transplant model, CCL8-CCR8 blocking antibody, macrophage depletion, flow cytometry\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with blocking experiments in a defined in vivo transplant model; single study\",\n      \"pmids\": [\"35973731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Lactate induces CCL8 production in M2 tumor-associated macrophages via AKT/ERK signaling; secreted CCL8 then activates CCR5 on colorectal cancer cells, triggering mTORC1 signaling to promote proliferation and metastasis; CCR5 antagonism or knockdown blocks these effects.\",\n      \"method\": \"qRT-PCR, Western blot, RNA-seq, wound healing assay, colony formation, CCR5 knockdown/antagonist, allograft mouse model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods defining CCL8/CCR5/mTORC1 pathway in vitro and in vivo; single study\",\n      \"pmids\": [\"38136340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL8 stimulates collagen production in fibroblasts via ERK1/2 phosphorylation; anti-CCL8 neutralizing antibody treatment in an IgG4-RD mouse model reduces salivary gland inflammation and fibrosis scores.\",\n      \"method\": \"Recombinant CCL8 stimulation of NIH/3T3 fibroblasts, Western blot for collagen and p-ERK1/2, anti-CCL8 antibody treatment in LAT Y136F knockin mice\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanism with in vivo antibody blockade confirming fibrotic role; single study\",\n      \"pmids\": [\"34391459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"F. nucleatum induces CCL8 expression in macrophages via TLR4/NF-κB signaling; iron attenuates the inhibitory phosphorylation of NF-κB p65 by activating serine/threonine phosphatases, thereby augmenting F. nucleatum-induced CCL8 production in tumor-associated macrophages.\",\n      \"method\": \"Macrophage infection assay, TLR4/NF-κB pathway inhibition, iron supplementation/depletion, Western blot for p-p65\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of signaling pathway with pharmacological and nutritional perturbations; single study\",\n      \"pmids\": [\"36136589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Stromal cell-derived CCL8 cooperates with CXCL12 to attract hematopoietic progenitors that differentiate into regulatory dendritic cells; Leishmania donovani infection of bone marrow stromal cells enhances CCL8 production, increasing regulatory DC development.\",\n      \"method\": \"Murine leishmaniasis model, splenic stromal cell CCL8 production measurement, hematopoietic progenitor migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional migration and differentiation assay in infection context; single study\",\n      \"pmids\": [\"20624948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mouse orphan receptor L-CCR expressed in HEK293 cells responds to CCL2, CCL7, CCL8, and CCL5 with pertussis toxin-sensitive chemotaxis and Ca2+ transients; biotinylated CCL2 binds to L-CCR-expressing cells, identifying L-CCR as a functional receptor for CCL8.\",\n      \"method\": \"Receptor transfection in HEK293, chemotaxis assay, Ca2+ measurement, pertussis toxin inhibition, biotinylated ligand binding\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional receptor assay in transfected cells with multiple readouts; single study for mouse ortholog receptor\",\n      \"pmids\": [\"12885941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CCL8 is upregulated in mast cells when co-cultured with endometrial cells; CCL8 promotes migration of endometrial epithelial and stromal cells and increases angiogenesis of endothelial cells; CCR1 (receptor for CCL8) is overexpressed in ectopic endometrium and co-localizes with blood vessels; CCR1 inhibition suppresses endometriosis development and angiogenesis in vivo.\",\n      \"method\": \"Mast cell-endometrial cell co-culture with mRNA sequencing, Transwell migration assay, CCK-8 proliferation, tube formation assay, mouse endometriosis model, CCR1 inhibition in vivo\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanism with in vivo validation; single study\",\n      \"pmids\": [\"32768961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL8 deficiency in host mice receiving allogeneic bone marrow transplantation significantly reduces acute GVHD mortality (90% vs 23.4% survival), attenuates liver dysfunction and pathology, and is associated with a surge of plasma IL-6 in CCL8-/- recipients, suggesting CCL8 promotes GVHD pathogenesis potentially through IL-6 cascade.\",\n      \"method\": \"CCL8 knockout mice, allogeneic BMT model, survival analysis, histopathological scoring, cytokine ELISA\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined survival and pathological readout; single study\",\n      \"pmids\": [\"34808257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Allergic airway inflammation decreases lung Klebsiella pneumoniae burden in a CCL8-dependent manner; neutralization of CCL8 reverses this protective effect, identifying a novel role for CCL8 in lung antibacterial immunity.\",\n      \"method\": \"Mouse allergic airway inflammation model, K. pneumoniae infection, CCL8 neutralizing antibody, bacterial burden measurement\",\n      \"journal\": \"Infection and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization with bacterial burden readout; single study\",\n      \"pmids\": [\"24958709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Dendritic cells express CCL8 upon stimulation by allogeneic CD4+ T cells through MHC class II molecule interactions (cell-contact dependent); the early plasma CCL8 level (day 5) after allogeneic BMT correlates with GVHD survival and pathological scores.\",\n      \"method\": \"Dendritic cell-T cell co-culture, anti-MHC class II blocking, allogeneic BMT mouse model, CCL8 immunoassay\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro co-culture mechanistic study with in vivo correlation; single study\",\n      \"pmids\": [\"21782767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL8 secreted by ECFCs induces IL-8 production in TNBC cells via c-Jun transcription factor; IL-8 reciprocally induces CCL8 in ECFCs, forming a positive feedback loop that promotes invasion, angiogenesis, and tumorigenicity of both cell types.\",\n      \"method\": \"Indirect co-culture, cytokine antibody array, RT-PCR, siRNA knockdown, xenograft model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — signaling defined with pathway inhibition/siRNA, c-Jun identified, in vivo xenograft confirmation; single study\",\n      \"pmids\": [\"33833397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In myocardial infarction, P16+ senescent fibroblasts and macrophages are the main sources of CCL8; CCL8 recruits cytotoxic CD8+ T cells and NK cells to the infarcted heart, promoting cardiomyocyte apoptosis and adverse remodeling. CCL8 blockade or Ccl8 deletion in P16+ cells reduces CD8+ T cell infiltration and improves cardiac repair.\",\n      \"method\": \"p16-CreER reporter mice, dual-recombinase intersectional ablation, scRNA-seq, bulk RNA-seq, CCL8 neutralization antibody, CD8+ T cell depletion, CellChat intercellular communication analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models plus neutralization antibody, single-cell and bulk transcriptomics, defined cellular mechanism\",\n      \"pmids\": [\"41766526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Muscle cell-derived (Pax7+, Myf5+, or MyoD+ myogenic progenitor cell) CCL8 negatively regulates myogenic differentiation; Cas9-mediated Ccl8 depletion in myogenic progenitor cells accelerates muscle regeneration after injury, and intramuscular recombinant CCL8 reverses this phenotype.\",\n      \"method\": \"Ccl8 knockdown in C2C12 myoblasts, AAV9-sgRNA Ccl8 gene editing in Pax7+/Myf5+/MyoD+ cells, barium chloride injury model, single-cell transcriptomics of existing datasets, recombinant CCL8 injection rescue\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple myogenic lineage-specific KO models with functional rescue; single study\",\n      \"pmids\": [\"39051762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In esophageal cancer, CBX6 promotes CCL8 expression by interacting with SMARCD1 to remodel chromatin at the CCL8 promoter; CCL8 secretion leads to CD8+ T cell exhaustion and tumor progression.\",\n      \"method\": \"Cbx6 knockdown, co-culture with CD8+ T cells, chromatin remodeling assay, tissue microarray, in vivo tumorigenesis\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — chromatin remodeling mechanism inferred without direct ChIP for CCL8 promoter; single study\",\n      \"pmids\": [\"41219497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HSP90 interacts with transcription factor STAT1 and stabilizes it, driving CCL8 expression; STAT1 knockdown attenuates CCL8 upregulation and macrophage recruitment in atrial cardiomyocytes, placing HSP90-STAT1-CCL8 in a pathway mediating atrial inflammation during hypertension-induced atrial fibrillation.\",\n      \"method\": \"RNA sequencing, HSP90 inhibitor 17AAG, STAT1 knockdown, AngII mouse AF model, HL-1 cell line experiments\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — STAT1 knockdown defining pathway in vitro and in vivo; single study\",\n      \"pmids\": [\"41720180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP18 stabilizes SOCS1 by inhibiting its ubiquitination and degradation, suppressing CCL8 production in alveolar type II epithelial cells through ERK-STAT3 signaling; USP18-deficient AT2 cells increase CCL8 expression, promoting Th2 cell and eosinophil recruitment; CCL8 knockdown in USP18 KO mice alleviates asthma symptoms.\",\n      \"method\": \"USP18 knockout mice, AT2-specific CCL8 knockdown, exogenous CCL8 treatment, SOCS1 ubiquitination assay, ERK-STAT3 pathway inhibition, Th2/eosinophil flow cytometry\",\n      \"journal\": \"Respiratory research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + pathway mechanistic rescue experiments; single study\",\n      \"pmids\": [\"41354823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"JMJD1A (histone demethylase) cooperates with STAT1 to demethylate H3K9me2 on the IRF1 promoter, inducing IRF1 expression; IRF1 and JMJD1A together demethylate H3K9me2 on the CCL8 promoter to drive CCL8 expression in colonic epithelial cells, promoting macrophage and CD4+ T cell recruitment during enteric infection.\",\n      \"method\": \"JMJD1A-/- mice, C. rodentium infection, ChIP for H3K9me2, IRF1 overexpression/knockdown, macrophage depletion, mucosal immune cell analysis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP validation of epigenetic regulation at CCL8 promoter with genetic KO in vivo; single study\",\n      \"pmids\": [\"41779805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"miR-425 suppresses ZNF24 expression in astrocytes, which downregulates CCL8 secretion; reduced CCL8 leads to astrocyte activation that promotes breast cancer brain metastasis in vivo.\",\n      \"method\": \"miR-425 overexpression/inhibition in breast cancer EVs, astrocyte co-culture, ZNF24 knockdown, CCL8 ELISA, mouse brain metastasis model, immunohistochemistry\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic cascade validated in vitro and in vivo, miR-425-ZNF24-CCL8 axis confirmed; single study\",\n      \"pmids\": [\"41977380\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL8 (MCP-2) is a CC chemokine that signals through multiple receptors (CCR1, CCR2, CCR3, CCR5, and in mice CCR8) via pertussis toxin-sensitive G-protein pathways to recruit monocytes, T lymphocytes, eosinophils, basophils, NK cells, and regulatory T cells; its transcription is driven by IFN-γ/IL-1β synergy through defined promoter elements (including STAT1/IRF1/JMJD1A-mediated chromatin remodeling), repressed by BLIMP1 and microRNAs (miR-146a, miR-92a), and its activity is modulated by extracellular proteolytic truncation (losing N-terminal residues) that converts the chemokine from an agonist to a CCR2 antagonist, while downstream it activates ERK, NF-κB, PI3K/AKT, and mTORC1 pathways in target cells to regulate inflammation, tumor microenvironment remodeling, tissue fibrosis, and host defense.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CCL8 (MCP-2) is a CC chemokine that functions as a broad-spectrum leukocyte chemoattractant, orchestrating innate and adaptive immune cell recruitment in inflammation, infection, tissue repair, and tumor microenvironment remodeling. Originally isolated as a monocyte-selective chemoattractant [PMID:1613466], CCL8 signals through multiple CC chemokine receptors—CCR1, CCR2, CCR3, CCR5, and in mice CCR8—via pertussis toxin-sensitive G-protein pathways to recruit monocytes, T lymphocytes (CD4+, CD8+, γ/δ, Treg), eosinophils, basophils, NK cells, and hematopoietic progenitors [PMID:7926371, PMID:9115216, PMID:9790730, PMID:21217759, PMID:24477914, PMID:27471618]. CCL8 transcription is induced by IFN-γ (synergizing with IL-1β or TLR ligands) through a defined promoter region and is regulated by STAT1, IRF1, JMJD1A-mediated H3K9me2 demethylation at its promoter, ERK/p38 MAPK stabilization of its mRNA, and repressed by BLIMP1 and microRNAs (miR-146a, miR-92a, miR-345-5p) targeting its 3′ UTR [PMID:10496322, PMID:18981157, PMID:24477914, PMID:29550454, PMID:30841468, PMID:41779805]. Extracellular proteolytic truncation of full-length CCL8(1–76) to CCL8(6–75) converts it from an agonist to a CCR2-selective antagonist that blocks ERK signaling and induces receptor internalization, establishing a built-in negative regulatory mechanism [PMID:19224633].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"The identity of CCL8 as a distinct monocyte chemoattractant was unknown; its purification and sequencing established it as a novel CC chemokine structurally related to MCP-1 with selective monocyte-recruiting activity.\",\n      \"evidence\": \"Protein purification from osteosarcoma supernatants, peptide sequencing, Boyden chamber chemotaxis, intradermal injection in rabbits\",\n      \"pmids\": [\"1613466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown\", \"Mechanism of monocyte selectivity undefined\", \"In vivo physiological role not tested\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Whether CCL8 acted on cell types beyond monocytes was uncertain; demonstration that it attracts CD4+ and CD8+ T cells, eosinophils, and basophils via pertussis toxin-sensitive GPCRs and cross-desensitizes with MCP-1/RANTES receptors revealed it as a broad-spectrum chemoattractant with overlapping receptor usage.\",\n      \"evidence\": \"Boyden chamber chemotaxis, Ca2+ flux, pertussis toxin inhibition, cross-desensitization on T cells, eosinophils, and basophils\",\n      \"pmids\": [\"7926371\", \"7535823\", \"7514401\", \"7531149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific receptor identities not molecularly defined\", \"Relative receptor preference hierarchy unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The molecular identity of CCL8 receptors was resolved by demonstrating direct high-affinity binding to CCR1 and CCR2B in transfected cells with functional chemotactic responses.\",\n      \"evidence\": \"Radioligand binding and chemotaxis in CCR1- and CCR2B-transfected HEK293 cells\",\n      \"pmids\": [\"9115216\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCR3 and CCR5 interactions not yet characterized\", \"In vivo receptor preference not determined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Whether CCL8 engaged CCR5 was unknown; binding and functional assays demonstrated high-affinity CCR5 agonism, HIV-1 gp120 competition, and preferential CCR5 use on activated T cells, expanding the receptor repertoire.\",\n      \"evidence\": \"Radioligand binding to CCR5 transfectants, gp120 competition, anti-CCR5 mAb blocking, chemotaxis\",\n      \"pmids\": [\"9790730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCR3 affinity not quantitated\", \"Physiological relevance of HIV coreceptor blocking not tested in vivo\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"The transcriptional regulation of CCL8 was undefined; promoter deletion mapping identified an IFN-γ-responsive element between −340 and −301 and demonstrated synergistic induction by IFN-γ plus IL-1β.\",\n      \"evidence\": \"Luciferase reporter assays, EMSA in fibroblasts and osteosarcoma cells\",\n      \"pmids\": [\"10496322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific transcription factors binding the element not identified\", \"Post-transcriptional regulation unexplored\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The signaling pathways controlling CCL8 mRNA accumulation were clarified: oncostatin M induces CCL8 via ERK1/2-driven c-Jun/c-Fos transcription and p38-mediated mRNA stabilization through tristetraprolin inhibition.\",\n      \"evidence\": \"MAPK inhibitors, siRNA knockdown of c-Jun/c-Fos, mRNA stability assays in dermal fibroblasts\",\n      \"pmids\": [\"18981157\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in macrophages or other major CCL8 producers unknown\", \"Direct tristetraprolin-CCL8 mRNA interaction not shown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A key question was whether CCL8 activity is modulated post-secretion; discovery that extracellular processing truncates CCL8(1–76) to CCL8(6–75), converting it from agonist to CCR2 antagonist, established a built-in negative feedback mechanism.\",\n      \"evidence\": \"N-terminal sequencing of truncated forms, Ca2+ and ERK signaling via CCR1/2/3/5 transfectants, chemotaxis, receptor internalization assays\",\n      \"pmids\": [\"19224633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the responsible protease not determined\", \"In vivo relevance of truncated form not demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Species-specific receptor usage was resolved when mouse CCL8 was shown to be a CCR8 agonist (not CCR2), recruiting Th2 cells to allergen-inflamed skin, with Ccl8−/− and Ccr8−/− mice showing reduced eosinophilic inflammation.\",\n      \"evidence\": \"Ccl8−/− and Ccr8−/− mouse atopic dermatitis models, adoptive transfer, receptor signaling assays\",\n      \"pmids\": [\"21217759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether human CCL8 also signals through CCR8 not established\", \"Structural basis for species-specific receptor selectivity unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Whether CCL8 transcription is tonically repressed was answered by showing BLIMP1 directly represses CCL8 in macrophages; Ccl8−/− mice demonstrated CCL8 recruits γ/δ T cells producing IL-17F for Listeria clearance.\",\n      \"evidence\": \"Conditional Blimp1 KO macrophages, transcriptome analysis, Ccl8−/− mice, Listeria infection, γ/δ T cell depletion\",\n      \"pmids\": [\"24477914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BLIMP1 binding site on CCL8 promoter not mapped\", \"Mechanism of γ/δ T cell chemotaxis to CCL8 (receptor identity) not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Post-transcriptional control of CCL8 by miRNAs was established: miR-146a targets CCL8 3′ UTR in microglia during HIV infection, and miR-92a suppression by HCMV LAcmvIL-10 de-represses CCL8 during viral latency.\",\n      \"evidence\": \"miRNA overexpression in primary microglial cells (PMID:20181935), secretome proteomics in myeloid progenitors (PMID:25253336)\",\n      \"pmids\": [\"20181935\", \"25253336\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"miR-146a direct luciferase validation for CCL8 not shown in the 2010 study\", \"Quantitative contribution of miRNA regulation vs. transcriptional induction not compared\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CCL8 was placed in visceral pain circuitry: spinal CCL8 acting through CCR5/ERK mediates colitis-induced hyperalgesia, and miR-146a-5p directly targets CCL8 3′ UTR (confirmed by dual-luciferase) to suppress this pathway.\",\n      \"evidence\": \"Dual-luciferase reporter assay, intrathecal CCL8 siRNA and miR-146a agomir, colorectal distension pain threshold in TNBS colitis model\",\n      \"pmids\": [\"29550454\", \"29037608\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type producing spinal CCL8 (neuron vs. glia) not definitively resolved\", \"Whether CCL8/CCR5 pain signaling operates in humans unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CCL8's role in tumor immune microenvironments was mechanistically dissected: hypoxia-induced ZEB1 activates CCL8 transcription in cancer cells to recruit macrophages via CCR2/NF-κB, and miR-345-5p directly targets CCL8 3′ UTR to restrain pancreatic cancer NF-κB-driven proliferation.\",\n      \"evidence\": \"Macrophage migration assays, luciferase reporter for miR-345-5p, NF-κB pathway analysis in cervical and pancreatic cancer models\",\n      \"pmids\": [\"31263103\", \"30841468\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZEB1 directly binds CCL8 promoter not shown by ChIP\", \"NF-κB activation downstream of CCL8 lacks receptor specificity assignment\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CCL8's pro-fibrotic function was established: CCL8 stimulates collagen production in fibroblasts via ERK1/2, and anti-CCL8 antibody reduces fibrosis in an IgG4-related disease model.\",\n      \"evidence\": \"Recombinant CCL8 stimulation, Western blot for collagen and p-ERK1/2, anti-CCL8 antibody in LAT Y136F knockin mice\",\n      \"pmids\": [\"34391459\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating fibrotic CCL8 signaling in fibroblasts not identified\", \"Whether CCL8 drives fibrosis independently of immune cell recruitment not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"CCL8 was shown to drive a self-amplifying macrophage-monocyte recruitment loop in kidney allografts: donor macrophage CCL8 recruits recipient monocytes that differentiate and produce more CCL8, then recruit CCR8+ T cells; blocking CCL8-CCR8 reduces graft inflammation.\",\n      \"evidence\": \"Allogeneic murine kidney transplant, CCL8-CCR8 blocking antibody, macrophage depletion, flow cytometry\",\n      \"pmids\": [\"35973731\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of CCR2 vs. CCR8 in monocyte vs. T cell recruitment not dissected\", \"Human relevance not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A tumor-metabolic axis for CCL8 was defined: lactate from tumor cells induces CCL8 in M2 macrophages via AKT/ERK, and CCL8 activates CCR5/mTORC1 on colorectal cancer cells to promote metastasis.\",\n      \"evidence\": \"RNA-seq, CCR5 knockdown/antagonist, allograft mouse model, colony formation and wound healing assays\",\n      \"pmids\": [\"38136340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether mTORC1 is the direct effector or requires intermediate signaling steps unknown\", \"Single study without independent replication\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Epigenetic and transcriptional control of CCL8 was deepened: JMJD1A/STAT1/IRF1 demethylate H3K9me2 at the CCL8 promoter in colonic epithelium during infection; HSP90 stabilizes STAT1 to drive CCL8 in atrial cardiomyocytes; senescent cell-derived CCL8 recruits cytotoxic CD8+ T cells to infarcted hearts.\",\n      \"evidence\": \"JMJD1A−/− mice with ChIP at CCL8 promoter (PMID:41779805); HSP90 inhibitor/STAT1 knockdown in HL-1 cells (PMID:41720180); p16-CreER mice with CCL8 neutralization and CD8 depletion post-MI (PMID:41766526)\",\n      \"pmids\": [\"41779805\", \"41720180\", \"41766526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether JMJD1A-IRF1 axis is specific to CCL8 or co-regulates other chemokines not tested\", \"STAT1 vs. IRF1 hierarchy in different cell types not resolved\", \"Therapeutic window for CCL8 blockade in cardiac repair unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the protease that truncates CCL8(1–76) to the antagonist CCL8(6–75) in vivo remains unknown, as does the structural basis for species-specific receptor selectivity (human CCR1/2/3/5 vs. mouse CCR8); a comprehensive understanding of how CCL8 receptor choice is determined in different tissue microenvironments is lacking.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease identity for N-terminal truncation not determined\", \"Structural basis for mouse CCR8 vs. human CCR2 selectivity not resolved\", \"No crystal structure of CCL8-receptor complex available\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 3, 6, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 3, 13, 17, 34, 37]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 12, 22, 27, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 27, 39]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CCR1\",\n      \"CCR2\",\n      \"CCR5\",\n      \"CCR3\",\n      \"CCR8\",\n      \"STAT1\",\n      \"IRF1\",\n      \"BLIMP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}